The Eurostars consortium will develop an instrument and method (system) that rapidly determines an individuals status (degree) of Sickle Cell Disease. It will mimic these conditions and measure the rigidifying of the Red Blood Cells. From an individuals sickling behaviour, personalized treatment plans can be developed to enhance the quality of life and reduce costs of treatment. In relation to an oxygen gradient, the instrument will measure sickling as a reduction in deformability of the red blood cells.

The main objective is to develop a novel ex vivo diagnostic for the treatment of sickle cell patients (SCOOP). The technology will be able to measure the tendency of a patient’s red blood cells (RBC) to sickle, which depends on the oxygen level in the blood, enabling personalised treatment on the specific sickle behavior of each individual patient, leading to a greatly improved quality of life and life expectancy.